• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项基于问卷的研究,全面评估中国罕见病患者和照护者的现状。

A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China.

机构信息

The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, People's Republic of China.

State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.

出版信息

Orphanet J Rare Dis. 2021 Jul 22;16(1):327. doi: 10.1186/s13023-021-01954-7.

DOI:10.1186/s13023-021-01954-7
PMID:34294091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8296703/
Abstract

BACKGROUND

There are over 16.8 million rare disease patients in China, representing a large community that should not be neglected. While the public lack the awareness of their existence and difficult status quo, for one reason that they exist as a rare and special group in our society, for another reason that all sectors of the community haven't introduced and propagandized them suitably. However, as a special group with more difficulties in all aspects than normal healthy persons, they need enough care and love from us. To provide a basis for policy-makers to better understand the status quo of rare disease patients and care-givers in China and to devise some new policies to improve their quality of life, a comprehensive analysis of the status quo, unmet needs, difficulty caused by the rare disease is essential.

METHODS

A questionnaire-based online study of patients and care-givers (usually family members) was performed. The questionnaire was composed of 116 questions, such as the diagnosis process, treatment access, financial burden, views on patients' organizations, and a series of standardized tests to assess the quality of their life, including the SF-36, PHQ-9, PHQ-15, GAD-7, and PSQI. To examine the influence of age, disease type, and relationship to patients on the scores in these tests, statistical analysis with a general linear model was conducted.

FINDINGS

A total of 1959 patients and care-givers participated in the survey, representing 104 rare diseases, such as lysosomal storage diseases, hemophilia, and muscular dystrophy diseases. The diagnosis was delayed for 1.4 ± 3.0 years, and patients experienced 1.6 ± 3.8 misdiagnoses between 3.2 ± 2.4 hospitals. The hospitals where diagnoses were made were highly concentrated in 10 large hospitals (43.8%) and 5 big cities (42.1%), indicating a significant inequality of medical resources. The disease often led to difficulty in social life, education, and employment, as well as financial burden that was seldom covered by medical insurance. A battery of standardized tests demonstrated poor health status, depression, somatization, anxiety, and sleeping issues among both patients and care-givers (p < 0.05). Statistical analysis of the questionnaire also showed that poor health, anxiety, depression, somatization, and sleeping problems were more prevalent in patients than in care-givers, and more prevalent in more severe diseases (e.g., hemophilia, Dravet) or undiagnosed than in other diseases.

INTERPRETATIONS

This study identified the lack of rare disease awareness and legislative support as the major challenge to rare diseases in China, and makes key recommendations for policy-makers, including legislating orphan drug act, raising rare disease awareness, providing sufficient and fair opportunities about education and employment, expanding the medical insurance coverage of treatments, and protecting rights in education and employment.

摘要

背景

中国有超过 1680 万的罕见病患者,这是一个庞大的群体,不容忽视。公众对他们的存在和艰难处境缺乏认识,一方面是因为他们作为社会中的一个特殊和罕见群体而存在,另一方面是因为社会各界没有适当地介绍和宣传他们。然而,作为一个在各方面都比正常健康人面临更多困难的特殊群体,他们需要我们给予足够的关爱。为了为政策制定者提供更好地了解中国罕见病患者和照顾者现状的依据,并制定一些新的政策来提高他们的生活质量,有必要对现状、未满足的需求以及罕见病带来的困难进行全面分析。

方法

对患者和照顾者(通常是家庭成员)进行了基于问卷的在线研究。问卷由 116 个问题组成,例如诊断过程、治疗途径、经济负担、对患者组织的看法以及一系列评估生活质量的标准化测试,包括 SF-36、PHQ-9、PHQ-15、GAD-7 和 PSQI。为了检查年龄、疾病类型和与患者的关系对这些测试中的分数的影响,使用一般线性模型进行了统计分析。

结果

共有 1959 名患者和照顾者参与了调查,代表了 104 种罕见疾病,如溶酶体贮积症、血友病和肌营养不良症等。诊断延迟了 1.4±3.0 年,患者在 3.2±2.4 家医院中经历了 1.6±3.8 次误诊。进行诊断的医院高度集中在 10 家大医院(43.8%)和 5 个大城市(42.1%),表明医疗资源分布极不均衡。这种疾病常常导致患者在社会生活、教育和就业方面遇到困难,并且经济负担很少得到医疗保险的覆盖。一系列标准化测试表明,患者和照顾者的健康状况均较差,存在抑郁、躯体化、焦虑和睡眠问题(p<0.05)。问卷的统计分析还表明,患者的健康状况、焦虑、抑郁、躯体化和睡眠问题比照顾者更严重,在更严重的疾病(如血友病、Dravet 综合征)或未确诊的疾病中比其他疾病更严重。

解释

本研究确定了罕见病意识和立法支持的缺乏是中国罕见病面临的主要挑战,并为政策制定者提出了关键建议,包括立法孤儿药法案、提高罕见病意识、提供充分和公平的教育和就业机会、扩大治疗的医疗保险覆盖范围以及保护教育和就业权利。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb72/8296703/e13922f3d030/13023_2021_1954_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb72/8296703/2371ae19ad57/13023_2021_1954_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb72/8296703/e13922f3d030/13023_2021_1954_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb72/8296703/2371ae19ad57/13023_2021_1954_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb72/8296703/e13922f3d030/13023_2021_1954_Fig2_HTML.jpg

相似文献

1
A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China.一项基于问卷的研究,全面评估中国罕见病患者和照护者的现状。
Orphanet J Rare Dis. 2021 Jul 22;16(1):327. doi: 10.1186/s13023-021-01954-7.
2
The urgent need to empower rare disease organizations in China: an interview-based study.中国迫切需要增强罕见病组织的能力:一项基于访谈的研究。
Orphanet J Rare Dis. 2020 Oct 12;15(1):282. doi: 10.1186/s13023-020-01568-5.
3
Rare disease awareness and perspectives of physicians in China: a questionnaire-based study.中国医生对罕见病的认知和看法:一项基于问卷调查的研究。
Orphanet J Rare Dis. 2021 Apr 13;16(1):171. doi: 10.1186/s13023-021-01788-3.
4
Review of 11 national policies for rare diseases in the context of key patient needs.在关键患者需求背景下对11项国家罕见病政策的审查。
Orphanet J Rare Dis. 2017 Mar 31;12(1):63. doi: 10.1186/s13023-017-0618-0.
5
Is sub-national healthcare social protection sufficient for protecting rare disease patients? the case of China.国家以下层面的医疗保健社会保护是否足以保护罕见病患者?以中国为例。
Front Public Health. 2023 Jun 16;11:1198368. doi: 10.3389/fpubh.2023.1198368. eCollection 2023.
6
Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies.罕见病治疗方法的评估:社会偏好研究的系统文献综述。
Adv Ther. 2023 Feb;40(2):393-424. doi: 10.1007/s12325-022-02359-z. Epub 2022 Dec 1.
7
Health-related quality of life in early breast cancer.早期乳腺癌患者的健康相关生活质量
Dan Med Bull. 2010 Sep;57(9):B4184.
8
9
Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.日本作为超老龄化社会的领跑者:来自日本医学与医疗护理的视角
Geriatr Gerontol Int. 2015 Jun;15(6):673-87. doi: 10.1111/ggi.12450. Epub 2015 Feb 5.
10
Patient Access to Orphan Drugs Covered by Medical Insurance in China: Real-World Evidence From Patient Survey.中国患者获取医疗保险覆盖的罕见病药物情况:来自患者调查的真实世界证据
Value Health Reg Issues. 2023 Mar;34:71-77. doi: 10.1016/j.vhri.2022.10.008. Epub 2022 Dec 30.

引用本文的文献

1
Rare but not to be overlooked: Epidemiology and strategies for rare dermatological diseases in China.罕见但不容忽视:中国罕见皮肤病的流行病学与应对策略
Intractable Rare Dis Res. 2025 Aug 31;14(3):151-161. doi: 10.5582/irdr.2025.01039.
2
The impact of rare diseases on the quality of life in paediatric patients: current status.罕见病对儿科患者生活质量的影响:现状
Front Public Health. 2025 Mar 24;13:1531583. doi: 10.3389/fpubh.2025.1531583. eCollection 2025.
3
Individualizing the lifesaving journey for calciphylaxis: addressing rapidly progressive attacks with multidimensional and AI research for regenerative medicine.

本文引用的文献

1
Rare disease awareness and perspectives of physicians in China: a questionnaire-based study.中国医生对罕见病的认知和看法:一项基于问卷调查的研究。
Orphanet J Rare Dis. 2021 Apr 13;16(1):171. doi: 10.1186/s13023-021-01788-3.
2
Biomarkers in Rare Diseases.罕见病的生物标志物。
Int J Mol Sci. 2021 Jan 12;22(2):673. doi: 10.3390/ijms22020673.
3
The urgent need to empower rare disease organizations in China: an interview-based study.中国迫切需要增强罕见病组织的能力:一项基于访谈的研究。
为钙过敏症量身定制挽救生命之旅:通过再生医学的多维度和人工智能研究应对快速进展性发作。
Ren Fail. 2024 Dec;46(2):2392846. doi: 10.1080/0886022X.2024.2392846. Epub 2024 Sep 5.
4
Reprogramming the future: Capitalizing on embryo culture by advancing stem cell technologies in the fight against rare genetic disorders.重塑未来:通过推进干细胞技术利用胚胎培养来对抗罕见遗传疾病。
Intractable Rare Dis Res. 2024 May 31;13(2):117-120. doi: 10.5582/irdr.2023.01074.
5
Barriers to prophylactic treatment among patients with haemophilia A in Shandong Province, China: a qualitative study.中国山东省甲型血友病患者预防性治疗的障碍:一项定性研究。
Orphanet J Rare Dis. 2023 Aug 3;18(1):226. doi: 10.1186/s13023-023-02838-8.
6
Sleep quality, anxiety, symptoms of depression, and caregiver burden among those caring for patients with Dravet syndrome: a prospective multicenter study in Germany.照料德拉韦综合征患者的人群的睡眠质量、焦虑、抑郁症状和照护者负担:德国一项前瞻性多中心研究。
Orphanet J Rare Dis. 2023 Apr 29;18(1):98. doi: 10.1186/s13023-023-02697-3.
7
Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges.加强全球罕见病诊断和治疗的公平可及性:证据、政策和挑战综述。
Int J Environ Res Public Health. 2023 Mar 8;20(6):4732. doi: 10.3390/ijerph20064732.
8
Literature Review on Health Emigration in Rare Diseases-A Machine Learning Perspective.罕见病健康移民的文献综述——基于机器学习的视角。
Int J Environ Res Public Health. 2023 Jan 30;20(3):2483. doi: 10.3390/ijerph20032483.
9
Prevalence of depression and anxiety, and their relationship to social support among patients and family caregivers of rare bone diseases.罕见骨病患者和家属的抑郁和焦虑患病率,以及与社会支持的关系。
Orphanet J Rare Dis. 2023 Jan 26;18(1):18. doi: 10.1186/s13023-022-02611-3.
10
The Role of Associations in Reducing the Emotional and Financial Impact on Parents Caring for Children with Duchenne Muscular Dystrophy: A Cross-Cultural Study.协会在减轻照顾杜氏肌营养不良症患儿的父母的情感和经济影响方面的作用:一项跨文化研究。
Int J Environ Res Public Health. 2022 Sep 28;19(19):12334. doi: 10.3390/ijerph191912334.
Orphanet J Rare Dis. 2020 Oct 12;15(1):282. doi: 10.1186/s13023-020-01568-5.
4
Towards universal health coverage: lessons from 10 years of healthcare reform in China.迈向全民健康覆盖:中国 10 年医改经验教训。
BMJ Glob Health. 2020 Mar 19;5(3):e002086. doi: 10.1136/bmjgh-2019-002086. eCollection 2020.
5
The Orphan Drug Act: An Appropriate Approval Pathway for Treatments of Rare Diseases?《孤儿药法案》:罕见病治疗的合适审批途径?
Hosp Pharm. 2019 Oct;54(5):283-284. doi: 10.1177/0018578719867665. Epub 2019 Aug 2.
6
Incidence and prevalence of 121 rare diseases in China: Current status and challenges.中国121种罕见病的发病率和患病率:现状与挑战
Intractable Rare Dis Res. 2019 May;8(2):89-97. doi: 10.5582/irdr.2019.01066.
7
Network established to collaborate on diagnosis and treatment of rare diseases in China: A strategic alliance backed by tiered healthcare is the key to the future.中国成立罕见病诊疗协作网络:分级医疗支持下的战略联盟是未来关键。
Intractable Rare Dis Res. 2019 Feb;8(1):78-79. doi: 10.5582/irdr.2019.01024.
8
China issues the National Essential Medicines List (2018 edition): Background, differences from previous editions, and potential issues.中国发布《国家基本药物目录(2018 年版)》:背景、与前几版的区别及潜在问题。
Biosci Trends. 2018;12(5):445-449. doi: 10.5582/bst.2018.01265.
9
China has officially released its first national list of rare diseases.中国正式发布了首个国家罕见病目录。
Intractable Rare Dis Res. 2018 May;7(2):145-147. doi: 10.5582/irdr.2018.01056.
10
Coping Strategies, Stress, and Support Needs in Caregivers of Children with Mucopolysaccharidosis.黏多糖贮积症患儿照料者的应对策略、压力及支持需求
JIMD Rep. 2018;42:89-97. doi: 10.1007/8904_2017_87. Epub 2018 Jan 4.